// App-Quantinova.ai

POS0092 (2021) : HERPES ZOSTER IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM

Researchers

Presenter

  • K. Winthrop

Principal Investigators

  • M. H. Buch

  • J. Curtis

  • G. R. Burmester

  • D. Aletaha

  • K. Amano

  • A. Pechonkina

  • L. Ye

  • Q. Gong

  • R. Besuyen

  • J. Galloway

Medical Centers

  • Oregon Health and Science University, Division of Infectious Diseases, Portland, United States of America

  • School of Biological Sciences The University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom

  • University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL

  • Charite University Hospital, Rheumatology and Clinical Immunology, Berlin, Germany.

  • Medical University of Vienna Clinical Division of Oncology, Department of Medicine, Vienna, Austria

  • Saitama Medical University, Department of Rheumatology and Applied Immunology, Saitama, Japan

  • Gilead Sciences, Inc., Clinical Development, Foster City, United States of America

  • Gilead Sciences, Inc., Biostatistics, Foster City, United States of America

  • Galapagos BV, Clinical Development, Leiden, Netherlands

  • King’s College London, Centre for Rheumatic Diseases, School of Immunology and Microbial Sciences, London, United Kingdom

Locations

  • United States

  • United Kingdom

  • Germany

  • Austria

  • Japan

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Infectious Diseases (ID)

Disease

  • Rheumatoid arthritis

  • Shingles

  • Inflammatory Arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Methotrexate

  • Adalimumab

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved